198 related articles for article (PubMed ID: 31772615)
21. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring.
Destro M; Scabrosetti R; Vanasia A; Mugellini A
Adv Ther; 2005; 22(1):32-43. PubMed ID: 15943220
[TBL] [Abstract][Full Text] [Related]
23. Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients: A K-MetS study.
Cho EJ; Sung KC; Kang SM; Shin MS; Joo SJ; Park JB
PLoS One; 2019; 14(4):e0214293. PubMed ID: 30964905
[TBL] [Abstract][Full Text] [Related]
24. A comparison of the effects of fixed dose vs. single-agent combinations on 24-h blood pressure variability.
Ulusoy S; Ozkan G; Konca C; Kaynar K
Hypertens Res; 2012 Nov; 35(11):1111-7. PubMed ID: 22786565
[TBL] [Abstract][Full Text] [Related]
25. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan.
Mancia G; Korlipara K; van Rossum P; Villa G; Silvert B
Blood Press Monit; 2002 Apr; 7(2):135-42. PubMed ID: 12048432
[TBL] [Abstract][Full Text] [Related]
26. A multicentre, 12-week study of imidapril and candesartan cilexetil in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
Palma-Gamiz JL; Pêgo M; Marquez E; Pujol M; Olivan J; Alegría E; Sagastagoitia-Gorostiza JD; Gonzalez-Juanatey JR
Clin Drug Investig; 2007; 27(6):407-17. PubMed ID: 17506591
[TBL] [Abstract][Full Text] [Related]
27. Modest blood pressure reduction with valsartan in acute ischemic stroke: a prospective, randomized, open-label, blinded-end-point trial.
Oh MS; Yu KH; Hong KS; Kang DW; Park JM; Bae HJ; Koo J; Lee J; Lee BC;
Int J Stroke; 2015 Jul; 10(5):745-51. PubMed ID: 25580869
[TBL] [Abstract][Full Text] [Related]
28. Cardioprotective effect of fimasartan, a new angiotensin receptor blocker, in a porcine model of acute myocardial infarction.
Sim DS; Jeong MH; Song HC; Kim J; Chong A; Bom HS; Jeong IS; Oh SG; Kim JM; Park DS; Kim JH; Lim KS; Kim MS; Ryu SH; Kim HK; Kim SS; Jang SY; Cho JY; Jeong HC; Lee KH; Park KH; Yoon NS; Yoon HJ; Kim KH; Hong YJ; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
J Korean Med Sci; 2015 Jan; 30(1):34-43. PubMed ID: 25552881
[TBL] [Abstract][Full Text] [Related]
29. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
30. Comparison of valsartan and amlodipine on ambulatory blood pressure variability in hypertensive patients.
Eguchi K; Imaizumi Y; Kaihara T; Hoshide S; Kario K
Clin Exp Hypertens; 2016; 38(8):721-724. PubMed ID: 27936949
[TBL] [Abstract][Full Text] [Related]
31. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial.
White WB; Murwin D; Chrysant SG; Koval SE; Davidai G; Guthrie R
Blood Press Monit; 2008 Feb; 13(1):21-7. PubMed ID: 18199920
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.
Park JB; Sung KC; Kang SM; Cho EJ
Am J Cardiovasc Drugs; 2013 Feb; 13(1):47-56. PubMed ID: 23344912
[TBL] [Abstract][Full Text] [Related]
33. Fimasartan: A New Angiotensin Receptor Blocker.
Lee HY; Oh BH
Drugs; 2016 Jul; 76(10):1015-22. PubMed ID: 27272555
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study.
Oh GC; Joo KW; Kim MA; Choi DJ; Kim YJ; Lee HY
Drug Des Devel Ther; 2020; 14():1341-1349. PubMed ID: 32308367
[TBL] [Abstract][Full Text] [Related]
35. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
[TBL] [Abstract][Full Text] [Related]
36. Renin-angiotensin system blockade safely reduces blood pressure in patients with minor ischemic stroke during the acute phase.
Nakamura T; Tsutsumi Y; Shimizu Y; Uchiyama S
J Stroke Cerebrovasc Dis; 2010; 19(6):435-40. PubMed ID: 20702114
[TBL] [Abstract][Full Text] [Related]
37. Multicenter Randomized Double-Blind Comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the Treatment of Isolated Systolic Hypertension in Elderly Patients: Results of the NEHIS Study.
Grassi G; Seravalle G; Brambilla G; Dell'Oro R; Trevano FQ; Fici F; van Bortel L; Mancia G
Adv Ther; 2017 Jan; 33(12):2173-2187. PubMed ID: 27771847
[TBL] [Abstract][Full Text] [Related]
38. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
Matsui Y; O'Rourke MF; Hoshide S; Ishikawa J; Shimada K; Kario K
Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
[TBL] [Abstract][Full Text] [Related]
39. A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy.
Kim KI; Shin MS; Ihm SH; Youn HJ; Sung KC; Chae SC; Nam CW; Seo HS; Park SM; Rhee MY; Kim MH; Cha KS; Kim YJ; Kim JJ; Chun KJ; Yoo BS; Park S; Shin ES; Kim DS; Il Kim D; Kim KH; Joo SJ; Jeong JO; Shin J; Kim CH
Clin Ther; 2016 Oct; 38(10):2159-2170. PubMed ID: 27502326
[TBL] [Abstract][Full Text] [Related]
40. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.
Malacco E; Santonastaso M; Varì NA; Gargiulo A; Spagnuolo V; Bertocchi F; Palatini P;
Clin Ther; 2004 Jun; 26(6):855-65. PubMed ID: 15262456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
